Clinical trial results of the iFuse-3D implant system demonstrated significant improvements in sacroiliac joint pain, function and quality of life at 24 months.
Five notes:
1. Results also indicated a notable reduction in opioid usage for patients with sacroiliac joint pain — 59 percent at baseline to 18 percent at 24 months.
2. Three physical function tests — active straight leg raise, five times sit-to-stand and transitional timed up-and-go — showed statistically significant improvements from baseline.
3. Of treated sacroiliac joints in the study, 100 percent showed bone integration to the iFuse-3D implant surface on the sacral and iliac side, and 77 percent of joints showed bony bridging across the joint, according to a July 7 news release.
4. "Early results from radiographic analysis of implant bone integration and SI joint bony bridging indicate that the enhanced porous surface of the iFuse-3D implant combined with the fenestrated structural design accelerates the rate of intraarticular fusion compared to the iFuse implant," said Vikas Patel, MD, principal investigator of the study.
5. IFuse, developed by sacropelvic company SI-Bone, has been evaluated in 90 peer-reviewed publications and has become the standard of care for sacroiliac joint fusion, according to the company.
Click here for more details on the clinical trial.